Page 96 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

CHAPTER 3 The Pathology of Neoplasia 75

reported to be as high as 19%, including differences in histogen- 4. Llamas-Velasco M, Paredes BE: Basic concepts in skin biopsy, Part
I, Actas Dermosifiliogr 103:12–20, 2012.
esis (tumor type) and benign versus malignant status, and up to 5. Pfeifer J, Wick M: The pathologic evaluation of neoplastic diseases.
37% for differences that would affect the prognosis or treatment
VetBooks.ir choices. 142,143 In Murphy GLW, Lenhard R, editors: Clinical oncology, Washing-
ton DC, 1995, Pan American Health Organization, pp 75–95.
The two major categories of errors that may occur at the
pathology laboratory are technical errors (e.g., improper labeling, 6. Mosby Inc:Mosby’s Medical Dictionary, ed 8th, St Louis, 2009, MO
Mosby.
2
trimming, other) and errors in interpretation of the tissue. If tis- 7. Burnett RC, Vernau W, Modiano JF, et al.: Diagnosis of canine
sue is processed improperly because of equipment malfunction or lymphoid neoplasia using clonal rearrangements of antigen recep-
because it is poorly sectioned, artifacts can occur that make the tor genes, Vet Pathol 40:32–41, 2003.
tissue specimen impossible to interpret. Errors in the pathologist’s 8. Jacobs RM, Messick H, Valli V: Tumors of the hemolymphatic sys-
interpretation may occur in the absence of relevant (or receipt of tem. In Meuten D, editor: Tumors in domestic animals, ed 4, Ames
erroneous) clinical information, or simply because the case is a Iowa, 2002, Iowa State Press, pp 119–198.
challenging one. If a pathology service is staffed by medical rather 9. Kiupel M, Webster JD, Bailey KL, et al.: Proposal of a 2-tier histo-
than veterinary pathologists, certain tumors may be misdiagnosed logic grading system for canine cutaneous mast cell tumors to more
(e.g., histiocytoma, MCT, transmissible venereal tumor, or peri- accurately predict biological behavior, Vet Pathol 48:147–155,
2011.
anal gland adenoma) because these do not have human coun- 10. Valli VE, Norris A, Jacobs RM, et al.: Pathology of canine bladder
terparts. Many pathologists informally seek opinions from other and urethral cancer and correlation with tumour progression and
pathologists when confronted with challenging cases. However, survival, J Comp Pathol 113:113–130, 1995.
the clinician, should never hesitate to ask for an official second opin- 11. Klobukowska HJ, Munday JS: High numbers of stromal cancer-
ion, nor should the original pathologist be offended by such a request. associated fibroblasts are associated with a shorter survival time in
A second or even a third pathologist can offer a different perspec- cats with oral squamous cell carcinoma, Vet Pathol 53:1124–1130,
tive on a difficult case and may suggest an alternative diagnosis, 2016.
confirm the diagnosis of the primary pathologist, or confirm that 12. Moore PF, Schrenzel MD, Affolter VK, et al.: Canine cutaneous
an accurate diagnosis is not possible and suggest additional ancil- histiocytoma is an epidermotropic langerhans cell histiocytosis that
lary tests for diagnostic clarification. Because patient management expresses CD1 and specific beta(2)-integrin molecules, Am J Pathol
148:1699–1708, 1996.
is affected significantly by the histopathologic diagnosis, it is not 13. Derwahl M, Studer H: Hyperplasia versus adenoma in endocrine
at all unreasonable for the clinician to request a second opinion. tissues: are they different? Trends Endocrin Met 13:23–28, 2002.
A misdiagnosis can result in costly, ineffective, and ultimately 14. Cullen JM, Breen M: An overview of molecular cancer pathol-
unnecessary treatments (e.g., surgery, chemotherapy, RT, other) genesis, prognosis, and diagnosis. In Meuten D, editor: Tumors in
that can cause morbidity for patients and unwarranted stresses domestic animals, ed 5, Ames Iowa, 2017, John Wiley & Sons Inc,
and costs for the client. Misdiagnoses may also result in insuf- pp 1–26.
ficient treatment, resulting in cancer progression and, perhaps of 15. Taylor DO, Dorn CR, Luis OH: Morphologic and biologic char-
greatest concern, unwarranted euthanasia. Considering these pos- acteristics of canine cutaneous histiocytoma, Cancer Res 29:83–92,
sible scenarios, second opinions are not only prudent but highly 1969.
recommended. 16. Cangul IT, Wijnen M, van Garderen E, et al.: Clinico-pathological
For optimal management of the veterinary cancer patient, it aspects of canine cutaneous and mucocutaneous plasmacytomas,
J Vet Med A 49:307–312, 2002.
is critical for the clinician to have a firm understanding of the 17. Johnson TO, Schulman FY, Lipscomb TP, et al.: Histopathology
procedures and processes involved in generating a diagnosis from and biologic behavior of pleomorphic cutaneous mast cell tumors
a biopsy sample—from the time of tissue acquisition to the gen- in fifteen cats, Vet Pathol 39:452–457, 2002.
eration and interpretation of the final report. An awareness of the 18. Ciekot PA, Powers BE, Withrow SJ, et al.: Histologically low-
limitations of histopathologic assessment and an understanding grade, yet biologically high-grade, fibrosarcomas of the mandible
of potentially beneficial ancillary tissue-based diagnostics also and maxilla in dogs - 25 cases (1982-1991), J Am Vet Med Assoc
are paramount. However, biopsy assessment is only one aspect 204:610–615, 1994.
of a case; other components (e.g., history, clinical presentation, 19. Gottfried SD, Popovitch CA, Goldschmidt MH, et al.: Metastatic
imaging or other diagnostic results, comorbidities) all should be digital carcinoma in the cat: a retrospective study of 36 cats (1992-
1998), J Am Anim Hosp Assoc 36:501–509, 2000.
considered collectively. Important factors are the willingness and 20. Fajardo LF, Berthrong M, Anderson RE: Differential diagnosis
ability of the clinician and pathologist to work collaboratively, of atypical cells in irradiated tissues. In Fajardo LF, Berthrong M,
with mutually open and receptive communication, to establish Anderson RE, editors: Radiation pathology New York, Oxford Uni-
the most accurate diagnosis and optimal care for the veterinary versity Press, 2001, pp 421–430.
cancer patient. 21. Patnaik AK, Ehler WJ, Macewen EG: Canine cutaneous mast-cell
tumor - morphologic grading and survival-time in 83 dogs, Vet
Pathol 21:469–474, 1984.
References 22. Kuntz CA, Dernell WS, Powers BE, et al.: Prognostic factors for
surgical treatment of soft-tissue sarcomas in dogs:75 cases (1986-
1. Kamstock DA, Ehrhart EJ, Getzy DM, et al.: Recommended 1996), J Am Vet Med Assoc 211:1147–1151, 1997.
guidelines for submission, trimming, margin evaluation, and 23. Coindre JM: Grading of soft tissue sarcomas - review and update,
reporting of tumor biopsy specimens in veterinary surgical pathol- Arch Pathol Lab Med 130:1448–1453, 2006.
ogy, Vet Pathol 48:19–31, 2011. 24. Romansik EM, Reilly CM, Kass PH, et al.: Mitotic index is predic-
2. Spitalnik PF, di Saint-Agnese PA: The Pathology of Cancer. In tive for survival for canine cutaneous mast cell tumors, Vet Pathol
Rubin BP, editor: Clinical oncology, a multi-disciplinary approach, 44:335–341, 2007.
ed 8th, Philadelphia W.B, 2001, Saunders Company, pp 47–61. 25. Elston LB, Sueiro FA, Cavalcanti JN, et al.: The importance of the
3. Clarke B, McCluggage WG: Iatrogenic lesions and artefacts in gyn- mitotic index as a prognostic factor for survival of canine cutaneous
aecological pathology, J Clin Pathol 62:104–112, 2009. mast cell tumors: a validation study, Vet Pathol 46:362–364, 2009.